Dexketoprofen trometamol - NSAIDs
Drug Class Description
Each tablet contains: Dexketoprofen trometamol 36.9 mg corresponding to dexketoprofen 25 mg.
Film coated tablets. Keral 25 mg: white, round, scored film-coated tablets. The tablets can be divided into equal halves.
Symptomatic treatment of pain of mild to moderate intensity, such as musculo-skeletal pain, dysmenorrhoea, dental pain.
According to the nature and severity of pain, the recommended dosage is generally 12.5 mg every 4-6 hours or 25 mg every 8 hours. The total daily dose should not exceed 75 mg.
Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms.
KERAL tablets are not intended for long term use and the treatment must be limited to the symptomatic period.
Concomitant administration with food delays the absorption rate of the drug, thus in case of acute pain it is recommended that administration is at least 30 minutes before meals.
In elderly patients it is recommended to start the therapy at the lower end of the dosage range (50 mg total daily dose). The dosage may be increased to that recommended for the general population only after good general tolerance has been ascertained.
Patients with mild to moderate hepatic dysfunction should start therapy at reduced doses (50 mg total daily dose) and be closely monitored. KERAL tablets should not be used in patients with severe hepatic dysfunction.
The initial dosage should be reduced to 50 mg total daily dose in patients with mildly impaired renal function. KERAL tablets should not be used in patients with moderate to severe renal dysfunction.
Children and adolescents:
KERAL tablets have not been studied in children and adolescents. Therefore, safety and efficacy have not been established and the product should not be used in children and adolescents.
KERAL tablets must not be administered in the following cases:
- patients hypersensitive to dexketoprofen, to any other NSAID, or to any of the excipients of the product.
- patients in whom substances with a similar action (e.g. aspirin, or other NSAIDs) precipitate attacks of asthma, bronchospasm, acute rhinitis, or cause nasal polyps, urticaria or angioneurotic oedema.
- patients with active or suspected peptic ulcer/haemorrhage or history of recurrent peptic ulcer/haemorrhage (two or more distinct episodes of proven ulceration or bleeding) or chronic dyspepsia.
- patients with history of gastrointestinal bleeding or perforation, related to previous NSAIDs therapy
- patients who have gastrointestinal bleeding or other active bleedings or bleeding disorders.
- patients with Crohn's disease or ulcerative colitis.
- patients with a history of bronchial asthma.
- patients with severe heart failure.
- patients with moderate to severe renal dysfunction.
- patients with severely impaired hepatic function.
- patients with haemorrhagic diathesis and other coagulation disorders.
- during pregnancy and lactation period.
The safe use in children and adolescents has not been established.
Administer with caution in patients with a history of allergic conditions.
The use of Keral with concomitant other NSAIDs including cyclooxygenase-2 selective inhibitors should be avoided.
Undesirable effects may be minimised by using the minimum effective dose for the shortest duration necessary to control symptoms.
Gastrointestinal bleeding, ulceration or perforation which can be fatal, have been reported with all NSAIDs at anytime during treatment, with or without warning symptoms or a previous history of serious gastrointestinal events. When gastrointestinal bleeding or ulceration occurs in patients receiving Keral, the treatment should be withdrawn.
The risk of gastrointestinal bleeding, ulceration or perforation is higher with increasing NSAID doses, in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation, and in the elderly.
Elderly: The elderly have an increased frequency of adverse reactions to NSAIDs especially gastrointestinal bleeding and perforation which may be fatal.
These patients should commence treatment on the lowest dose available.
As with all NSAIDs, any history of oesophagitis, gastritis and/or peptic ulcer must be sought in order to ensure their total cure before starting treatment with dexketoprofen trometamol.
Patients with gastrointestinal symptoms or history of gastrointestinal disease should be monitored for digestive disturbances, especially gastrointestinal bleeding.
NSAIDs should be given with care to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's disease) as their condition may be exacerbated (see section 4.8 undesirable effects).
Combination therapy with protective agents (e.g. misoprostol or proton pump inhibitors) should be considered for these patients, and also for patients requiring concomitant low dose aspirin, or other drugs likely to increase gastrointestinal risk.
Patients with a history of gastrointestinal toxicity, particularly when elderly, should report any unusual abdominal symptoms (especially gastrointestinal bleeding) particularly in the initial stages of treatment.
Caution should be advised in patients receiving concomitant medications which could increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin-reuptake inhibitors or anti-platelet agents such as aspirin.
All non-selective NSAIDs can inhibit platelet aggregation and prolong bleeding time via inhibition of prostaglandin synthesis. Therefore, the use of dexketoprofen trometamol in patients who are receiving other therapy that interferes with haemostasis, such as warfarin or other coumarins or heparins is not recommended.
As with all NSAIDs, it can increase plasma urea nitrogen and creatinine. As with other inhibitors of prostaglandin synthesis, it can be associated with adverse effects on the renal system which can lead to glomerular nephritis, interstitial nephritis, renal papillary necrosis, nephrotic syndrome and acute renal failure.
As with other NSAIDs, it can cause transient small increases in some liver parameters, and also significant increases in SGOT and SGPT. In case of a relevant increase in such parameters, therapy must be discontinued.
KERAL tablets should be administered with caution to patients suffering from haematopoietic disorders, systemic lupus erythematosus or mixed connective tissue disease.
As other NSAIDs, dexketoprofen can mask the symptoms of infectious diseases.
Caution should be exercised in patients with impairment of hepatic and/or renal functions as well as in patients with a history of hypertension and/or heart failure. In these patients, the use of NSAIDs may result in deterioration of renal function, fluid retention and oedema. Caution is also required in patients receiving diuretic therapy or those who could develop hypovolaemia as there is an increased risk of nephrotoxicity. Special caution should be exercised in patients with a history of cardiac disease, in particular those with previous episodes of heart failure as there is an increased risk of triggering heart failure.
Elderly patients are more likely to be suffering from impaired renal cardiovascular or hepatic function.
Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs. Patients appear to be at highest risk of these reactions early in the course of therapy, the onset of the reaction occurring in the majority of cases within the first month of treatment. Keral should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity.
As with other NSAIDS, the use of dexketoprofen trometamol may impair female fertility and is not recommended in women attempting to conceive. In women who have difficulties conceiving or who are undergoing investigation of infertility, withdrawal of dexketoprofen trometamol should be considered.
Appropriate monitoring and advice are required for patients with a history of hypertension and/or mild to moderate congestive heart failure as fluid retention and oedema have been reported in association with NSAIDs therapy.
Clinical trial and epidemiological data suggest that use of some NSAIDs (particularly at high doses and in long term treatment) may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke). There are insufficient data to exclude such a risk for Dexketoprofen Trometamol.
Patients with uncontrolled hypertension, congestive heart failure, established ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease should only be treated with Dexketoprofen Trometamol after careful consideration. Similar consideration should be made before initiating longer-term treatment of the patients with risk factors for cardiovascular disease (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking).
The following interactions apply to non-steroidal antiinflammatory drugs (NSAIDs) in general:
- Other NSAIDs, including high doses of salicylates ( 3 g/day): administration of several NSAIDs together may increase the risk of gastrointestinal ulcers and bleeding, via a synergistic effect.
- Anticoagulants: NSAIDs may enhance the effects of anti-coagulants, such as warfarin due to the high plasma protein binding of dexketoprofen and the inhibition of platelet function and damage to the gastroduodenal mucosa. If the combination cannot be avoided, close clinical observation and monitoring of laboratory values should be carried out.
- Heparins: increased risk of haemorrhage (due to the inhibition of platelet function and damage to the gastroduodenal mucosa). If the combination cannot be avoided, close clinical observation and monitoring of laboratory values should be carried out.
- Corticosteroids: there is an increased risk of gastrointestinal ulceration or bleeding
- Lithium (described with several NSAIDs): NSAIDs increase blood lithium levels, which may reach toxic values (decreased renal excretion of lithium). This parameter therefore requires monitoring during the initiation, adjustment and withdrawal of treatment with dexketoprofen.
- Methotrexate, used at high doses of 15 mg/week or more: increased haematological toxicity of methotrexate via a decrease in its renal clearance by antiinflammatory agents in general.
- Hydantoines and sulphonamides: the toxic effects of these substances may be increased.
Combinations requiring precautions:
- Diuretics, ACE inhibitors and angiotensin II receptor antagonists: Dexketoprofen may reduce the effect of diuretics and antihypertensive drugs. In some patients with compromised renal function (e. g. dehydrated patients or elderly patients with compromised renal function), the coadministration of agents that inhibit cyclo-oxygenase and ACE inhibitors or angiotensin II receptor antagonists may result in further deterioration of renal function, which is usually reversible. In case of combined prescription of dexketoprofen and a diuretic, it is essential to ensure that the patient is adequately hydrated and to monitor renal function at the start of the treatment.
- Methotrexate, used at low doses, less than 15 mg/week: increased haematological toxicity of methotrexate via a decrease in its renal clearance by antiinflammatory agents in general. Weekly monitoring of blood count during the first weeks of the combination. Increased surveillance in the presence of even mildly impaired renal function, as well as in the elderly.
- Pentoxyfilline: increased risk of bleeding. Increase clinical monitoring and check bleeding time more often.
- Zidovudine: risk of increased red cell line toxicity via action on reticulocytes, with severe anaemia occurring one week after the NSAID is started. Check CBC and reticulocyte count one to two weeks after starting treatment with the NSAID.
- Sulfonylureas: NSAIDs can increase the hypoglycaemic effect of sulfonylureas by displacement from plasma protein binding sites.
Associations needing to be taken into account:
- Beta-blockers: treatment with a NSAID may decrease their antihypertensive effect via inhibition of prostaglandin synthesis.
- Cyclosporin and tacrolimus: nephrotoxicity may be enhanced by NSAIDs via renal prostaglandin mediated effects. During combination therapy, renal function has to be measured.
- Thrombolytics: increased risk of bleeding.
- Anti-platelet agents and selective serotonin reuptake inhibitors (SSRIs): increased risk of gastrointestinal bleeding.
- Probenecid: plasma concentrations of dexketoprofen may be increased; this interaction can be due to an inhibitory mechanism at the site of renal tubular secretion and of glucuronoconjugation and requires adjustment of the dose of dexketoprofen.
- Cardiac Glycosides: NSAIDS may increase plasma glycoside concentration.
- Mifepristone: Because of a theoretical risk that prostaglandin synthetase inhibitors may alter the efficacy of mifepristone, NSAIDS should not be used for 8-12 days after mifepristone administration.
- Quinolone antibiotics: Animal data indicate that high doses of quinolones in combination with NSAIDS can increase the risk of developing convulsions.
The adverse reactions reported as at least possibly related with dexketoprofen trometamol in clinical trials, as well as the adverse reactions reported after the marketing of KERAL tablets are tabulated below, classified by system organ class and ordered by frequency:
|SYSTEM ORGAN CLASS||Common (1-10%)||Uncommon (0.1-1%)||Rare (0.01-0.1%)||Very rare / Isolated reports ( < 0.01%)|
|Blood and lymphatic system disorders||Neutropenia hrombocytopenia|
Immune system disorders
Anaphylactic reaction, including anaphylactic shock
Metabolism and nutrition disorders
|Psychiatric disorders||Insomnia, anxiety|
|Nervous system disorders||Headache, dizziness, somnolence||Paraesthesia, syncope|
|Eye disorders||Blurred vision|
|Ear and labyrinth disorders||Vertigo||Tinnitus|
|Respiratory, thoracic and mediastinal disorders||Bradypnoea||Bronchospasm, dyspnoea|
|Gastrointestinal disorders||Nausea and/or vomiting, abdominal pain, diarrhoea, dyspepsia.||Gastritis, constipation, dry mouth, flatulence||Peptic ulcer, peptic ulcer haemorrhage or peptic ulcer perforation||Pancreatitis|
|Hepatobiliary disorders||Hepatocellular damage|
|Skin and subcutaneous tissue disorders||Rash||Urticaria, acne, sweating increased||Stevens Johnson syndrome, toxic epidermal necrolysis (Lyell's syndrome), angioneurotic oedema, facial oedema, photosensitivity reactions, pruritus|
|Musculoskeletal and connective tissue disorders||Back pain|
|Renal and urinary disorders||Polyuria||Nephritis or nephrotic syndrome|
|Reproductive system and breast disorders >||Menstrual disorder, prostatic disorder|
|General disorders and administration site conditions||Fatigue, pain, asthenia, rigors, malaise||Peripheral oedema|
|Investigations||Liver function test abnormal|
Gastrointestinal: The most commonly-observed adverse events are gastrointestinal in nature. Peptic ulcers, perforation or gastrointestinal bleeding, sometimes fatal, particularly in the elderly, may occur. Nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, melaena, haematemesis, ulcerative stomatitis, exacerbation of colitis and Crohn's disease have been reported following administration. Less frequently, gastritis has been observed.
Oedema, hypertension and cardiac failure have been reported in association with NSAIDs treatment.
As with other NSAIDS, the following undesirable effects may appear: aseptic meningitis, which might predominantly occur in patients with systemic lupus erythematosus or mixed connective tissue disease; haematological reactions (purpura, aplastic and haemolytic anaemia, and rarely agranulocytosis and medullar hypoplasia).
Bullous reactions including Stevens Johnson Syndrome and Toxic Epidermal Necrolysis (very rare).
Clinical trial and epidemiological data suggest that use of some NSAIDs (particularly at high doses and in long term treatment) may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke).
A. Menarini Pharmaceuticals UK